share_log

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Benzinga ·  Mar 28, 2023 21:10

Gainers

  • Biomea Fusion (NASDAQ:BMEA) shares rose 60.7% to $24.79 during Tuesday's pre-market session. The company's market cap stands at $728.7 million.
  • Biodexa Pharmaceuticals (NASDAQ:BDRX) stock moved upwards by 54.7% to $0.73. The company's market cap stands at $5.0 million.
  • Viking Therapeutics (NASDAQ:VKTX) stock increased by 36.73% to $12.47. The company's market cap stands at $977.8 million.
  • Accelerate Diagnostics (NASDAQ:AXDX) shares increased by 15.99% to $0.58. The company's market cap stands at $57.4 million.
  • Addex Therapeutics (NASDAQ:ADXN) shares rose 14.81% to $1.24. The company's market cap stands at $23.8 million.
  • Intra-Cellular Therapies (NASDAQ:ITCI) shares moved upwards by 14.45% to $54.8. The company's market cap stands at $5.2 billion.

Losers

  • Monopar Therapeutics (NASDAQ:MNPR) stock declined by 49.0% to $1.52 during Tuesday's pre-market session. The market value of their outstanding shares is at $20.0 million. As per the news, the Q4 earnings report came out 3 days ago.
  • NexGel (NASDAQ:NXGL) shares fell 29.24% to $1.15. The company's market cap stands at $6.4 million. As per the press release, Q4 earnings came out yesterday.
  • OncoSec Medical (NASDAQ:ONCS) stock decreased by 24.25% to $2.0. The market value of their outstanding shares is at $5.9 million.
  • Trxade Health (NASDAQ:MEDS) stock decreased by 20.88% to $0.36. The company's market cap stands at $3.3 million. As per the news, the Q4 earnings report came out yesterday.
  • TC BioPharm (Holdings) (NASDAQ:TCBP) stock decreased by 19.66% to $1.41. The market value of their outstanding shares is at $3.1 million.
  • Harmony Biosciences (NASDAQ:HRMY) shares declined by 19.26% to $33.51. The market value of their outstanding shares is at $1.9 billion. See Also:

This article was generated by Benzinga's automated content engine and reviewed by an editor.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment